Recovery & Repair
Injury Recovery & Tissue Repair
A multi-compound protocol addressing the three bottlenecks in soft tissue repair: angiogenesis, fibroblast recruitment, and collagen quality. Built for acute injury, chronic joint conditions, post-surgical recovery, and athletic maintenance — with compound layers matched to the healing phase.
🎯 Research Target Populations
- ›Competitive athletes with acute soft tissue trauma (tendon, ligament, muscle)
- ›Physically demanding occupations with repetitive-stress or overuse injury
- ›Post-surgical recovery where standard healing timelines have stalled
- ›Chronic joint and connective tissue conditions unresponsive to conventional therapy
💊 Compounds in This Protocol
📋 Protocol Phases
1
Acute / Loading Phase
Weeks 1–4 — address inflammation and initiate angiogenesis
| Compound | Dose | Route | Frequency | Role |
|---|---|---|---|---|
| BPC-157CORE | 500 mcg – 1 mg/day | SubQ perilesional (near injury site preferred) | 1–2x daily | Core repair compound. Activates VEGFR2/eNOS angiogenesis axis and FAK-paxillin fibroblast recruitment at the injury site. Perilesional injection maximizes local paracrine signaling. |
| TB-500CORE | 2–5 mg | SubQ | 2x/week (loading) | Systemic tissue repair partner. G-actin sequestration promotes cell migration and angiogenesis throughout the body — reaches poorly vascularized tissue that perilesional BPC-157 cannot. |
| GHK-CuCORE | 1–2 mg | SubQ | Daily, pre-bed preferred | Collagen and elastin production. Activates TGF-β and bFGF wound-healing growth factors; upregulates antioxidant SOD. Addresses the collagen quality bottleneck that limits structural restoration. |
2
Proliferation Phase
Weeks 4–8 — GH axis support for systemic anabolic environment
| Compound | Dose | Route | Frequency | Role |
|---|---|---|---|---|
| BPC-157CORE | 500 mcg/day (reduce from loading) | SubQ perilesional | Once daily | Continues from Phase 1 at maintenance dose. |
| TB-500CORE | 1–2 mg | SubQ | Weekly (maintenance) | Transition from loading to maintenance dosing. |
| GHK-CuCORE | 1–2 mg | SubQ | Daily | Continues from Phase 1. |
| GH 2X Blend | 100 mcg each component | SubQ | Pre-bed, fasted | GH/IGF-1 optimization enhances systemic protein synthesis, satellite cell activation, and collagen production — the anabolic environment in which structural repair occurs. |
3
Remodeling / Maintenance Phase
Weeks 8–12 — structural integrity and ongoing support
| Compound | Dose | Route | Frequency | Role |
|---|---|---|---|---|
| BPC-157CORE | 250–500 mcg | SubQ | Once daily or EOD | Maintenance dosing for ongoing cytoprotection and tissue remodeling. |
| GHK-CuCORE | 1 mg | SubQ | EOD | Continued collagen remodeling and antioxidant support. |
| GH 2X Blend | 100 mcg each | SubQ | Pre-bed | Continues systemic anabolic support through the remodeling phase. |
⚙️ Compound Rationale
BPC-157
Activates VEGFR2 and FAK-paxillin simultaneously — driving angiogenesis and fibroblast recruitment at the injury site. Complete Achilles transection in rats recovered with superior biomechanics vs. untreated controls at every measured time point (Chang et al., 2011, PMID 21030672). Perilesional SubQ is preferred over systemic injection for musculoskeletal targets.
TB-500
Sequesters G-actin to promote cell migration and systemic angiogenesis, activates PI3K/Akt for cell survival, and upregulates MMPs for tissue remodeling. Complementary reach to BPC-157 — distributes systemically to poorly vascularized tissue.
GHK-Cu
Reactivates 31% of age-altered genes. Stimulates collagen I and III synthesis, elastin, and GAG production. Upregulates TGF-β, bFGF, and superoxide dismutase. Addresses collagen quality specifically, which BPC-157 and TB-500 do not directly target.
GH 2X Blend
GH/IGF-1 optimization provides the anabolic substrate for repair — increasing protein synthesis, satellite cell activation, and collagen production rates. The three requirements for complete tissue remodeling (vascular supply, cellular recruitment, structural matrix production) are collectively addressed by this compound combination.
📊 Monitoring & Assessment
Functional Milestones
- Pain score (0–10) at baseline and weekly
- Range of motion assessment
- Load tolerance testing at Week 4 and 8
Safety Watch
- Injection site reactions (BPC-157, TB-500)
- Pre-existing malignancy history — ABSOLUTE contraindication (VEGFR2 activation)
- Pregnancy — absolute contraindication
Reassessment Points
- Week 4: assess response, decide Phase 2 entry
- Week 8: evaluate functional improvement
- Week 12: full outcome assessment, cycle off 4 weeks
⚠️ Contraindications & Cautions
Active malignancy is an absolute contraindication for BPC-157, TB-500, and GHK-Cu — all three activate pro-angiogenic pathways (VEGFR2, PI3K/Akt) that theoretically support tumor vascularity.
Pregnancy: absolute contraindication for all compounds in this protocol.
Anticoagulant therapy: BPC-157 has documented interactions with coagulation dynamics. Discuss with a healthcare provider before use.
📚 Key References
Chang CH et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. PMID 21030672.
Gwyer D et al. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. PMID 30915550.
Pickart L & Margolina A. (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci.